PathGroup is committed to providing diagnostic expertise, precision technologies and innovative services and relationships — all to give our clinician partners personalized information for targeted therapies that lead to the best possible patient outcomes.

Led by recognized experts in the field of molecular diagnostics and bioinformatics, PathGroup works with leading individual and contract research partners in developing platforms for improved molecular intelligence. Our molecular diagnostics facility includes a dedicated CLIA validation laboratory to accelerate delivery of new tests and modalities to the physicians we serve and the patients they treat.

Through our collaboration with GenoSpace™/Thomson Reuters™ we can provide unparalleled information on genes, gene variants and their therapeutic implications, and place diverse real-time data into clinically actionable context for oncologists and researchers. Because the knowledgebase is continuously updated, new biological relevance for existing genes or new gene discoveries are captured and seamlessly integrated.

Our comprehensive menu of services for both solid and hematolymphoid malignancies means that physicians have molecular interrogation tools with turnaround times appropriate for responsible therapeutic intervention and patient management.

PathGroup molecular testing menu:

• Next-Generation Sequencing (NGS)
• Sanger Sequencing
• Pyrosequencing
• Quantitative and Real-Time Polymerase Chain Reaction (Q-PCR and QRT-PCR)
• Fluorescent In Situ Hybridization (FISH)

In addition, PathGroup supports this offering with oncology lab services, from clinical to genomic, all from a single source, with expertise and efficiency, across the continuum of patient care.

• Direct access to our team of pathologists
• Adherence to NCCN/CAP/ASCO/WHO testing guidelines and recommendations
• Clear, concise reporting
• Responsive customer service and extensive courier network